The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

For women everywhere, here's the true lowdown on Avastin for breast cancer

Straight talk in the Tower of Babel

I’m not sure I knew what breast cancer was the first time it took someone I cared about.

She was my mother’s closest friend. They’d grown up together and were there for each other’s weddings, when their children were born, and through all of life’s joys and hardships.

Phylis was young…maybe in her early 40s when it happened. And from diagnosis to when she passed was only about six months.

It’s a disease every woman fears. And it’s ruthless — striking when and how it wants, leaving women frightened and, too often, not knowing what is the best treatment option.

That’s why all the recent confusion over Avastin use for breast cancer is even more maddening.

There are women who passionately believe Avastin saved their lives. But still, an FDA panel voted to rescind approval of Avastin for breast cancer treatment.

And now an organization of oncologists has refuted the FDA, renewing a recommendation of the drug for breast cancer patients.

Imagine if you or someone you love were struggling with the decision of whether to include Avastin in your treatment plan — on top of facing a diagnosis of breast cancer.

So for every woman who feels aggravated by this Tower of Babel bickering, here’s a clear-eyed look at the REAL backstory of Avastin.

Delay of game

Avastin is a true blockbuster drug, used to treat several forms of cancer.

Last year’s sales of Avastin totaled nearly $7 billion, and $1 billion of that came from breast cancer patients.

Which brings us to Avastin’s controversy number one: It costs a patient between $50,000 and $100,000 per year.

Now, if every oncologist was completely honest and forthcoming with every breast cancer patient, they would make the cost of the drug very clear. Then they would carefully review potential adverse effects. Here’s a partial list from the Avastin website…

* Gastrointestinal perforation — sometimes fatal (an FDA release notes that perforations may occur in the nose, stomach, and intestines)
* Serious bleeding in the stomach or brain — sometimes fatal
* Severe high blood pressure that may cause stroke or heart problems — sometimes fatal
* Kidney problems — sometimes fatal
* Vision disturbances — including blindness

So you’ve got the outrageous cost coupled with nightmarish side effects. At that point, many patients would be out the door. But some would stay long enough to ask: “Does it work?”

Studies answer that question with mixed results. Like any drug, it works for some and not for others. But when an FDA panel reviewed four Avastin studies last year, they voted 12-to-1 in favor of withdrawing the agency’s 2008 approval of the drug for breast cancer.

The panel concluded, and the agency agreed, that the drug didn’t prolong overall survival, and whatever benefit there was in slowing disease progression was not sufficient “to outweigh the significant risk to patients.”

Game over? Not at all. Roche, the maker of Avastin, appealed the decision. So the FDA scheduled a public hearing this past June. And after two days of emotional testimony, the panel voted 6-0 to uphold the FDA’s decision to withdraw approval.

Now is the game over? No. Just the opposite.

The 800-lb gorilla

A few days ago, the National Comprehensive Cancer Network (NCCN) voted to continue its recommendation to use Avastin for breast cancer.

NCCN is a non-profit organization of oncologists. And for leading treatment centers, Medicare, and insurance companies, their recommendation is so powerful that it will actually overcome a retracted FDA approval.

I’ve got to admit, that’s impressive.

But before you make your decision about treatment, there’s one last detail you need to know…

NCCN is deeply entrenched in the Big Pharma culture.

According to Pharmalot, 10 of the 33 members of NCCN’s breast cancer panel have ties to Roche as “advisory board members, speakers, consultants, expert witnesses or having received clinical research support.”

And on the NCCN website’s listing of organizational relationships, you’ll find drug companies, large and small, including Pfizer, Wyeth, GlaxoSmithKline, Eli Lilly, Novartis, etc.

You won’t hear me say this very often, but I would listen to the FDA on this one. They had it wrong at first, but then they got it right. Twice.

Game over.

Sources: 
“NCCN Still Recommends Avastin For Breast Cancer” Ed Silverman, Pharmalot, 7/21/11, pharmalot.com

“U.S. FDA panel rejects Avastin for breast cancer” Reuters, 6/29/11, reuters.com 

Get a free copy of 5 Household Items that Cause Cancer

By texting HSI to 844-539-1128, you are providing your electronic signature expressly consenting to be called and texted (including by prerecorded messages, using an autodialer, and/or automated means) with alerts, stories, reports, and marketing communications from Institute of Health Sciences, LLC. and its authorized representatives at the phone number you provide, including landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also consent and unconditionally agree to our Privacy Policy and Terms of Use, including the arbitration provision and class action waiver contained therein. Msg&data rates may apply. 15 Msgs/Month. You are not required to agree to this as a condition of making a purchase.

Terms & Conditions

The following Terms and Conditions apply to your use of the website located at hsionline.com (the “website”) and any text messages that you send to or receive from the Institute of Health Sciences, L.L.C. These Terms and Conditions constitute a binding agreement (“Agreement”) between you (“you”) Institute of Health Sciences, L.L.C (“we”, “us”, etc.)  Please read these terms carefully. 

By providing your telephone number to us, texting us a short code listed on the website, or otherwise indicate your agreement to these Terms and Conditions, you are agreeing to the mandatory arbitration provision and class action waiver below. 

ARBITRATION IS MANDATORY AND THE EXCLUSIVE REMEDY FOR ANY AND ALL DISPUTES RELATED TO THIS WEBSITE, THIS AGREEMENT, AND ANY TELEPHONE CALLS, EMAILS, OR TEXT MESSAGES THAT YOU RECEIVE FROM OR ON BEHALF OF US, UNLESS SPECIFIED BELOW OR UNLESS YOU OPT-OUT.

Text Messaging and Telemarketing Terms and Conditions

When you provide your telephone number on this website or send a text message to us with or from a short-code, you agree to receive alerts and communications, and marketing messages including those sent via automated telephone dialing system, text messages, SMS, MMS, and picture messages from Institute of Health Sciences, L.L.C at the phone number you provide on this website or the phone number from which you text the short code, including on landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also agree to the mandatory arbitration provision and class action waiver below. Your consent is not required to purchase goods or services. Message & data rates may apply.

You may opt-out at any time by texting the word STOP to the telephone number from which you receive the text messages.  Call 1-888-213-0764 to learn more.  By providing your telephone number, you agree to notify us of any changes to your telephone number and update your account us to reflect this change. Your carrier may charge you for text messages and telephone calls that you receive, or may prohibit or restrict certain mobile features, and certain mobile features may be incompatible with your carrier or mobile device. Contact your carrier with questions regarding these issues.

Dispute Resolution by Binding Arbitration and Class Action Waiver

Any dispute relating in any way to telephone calls, emails, or text messages that you receive from or on behalf of Institute of Health Sciences, L.L.C this website, or this Agreement (collectively “Disputes”) shall be submitted to confidential arbitration and shall be governed exclusively by the laws of the State of Maryland, excluding its conflict of law provisions.  For the avoidance of doubt, all claims arising under the Telephone Consumer Protection Act and state telemarketing laws shall be considered “Disputes” that are subject to resolution by binding individual, confidential arbitration.

If a Dispute arises under this Agreement, you agree to first contact us at 1-888-213-0764 or help@hsionline.com. Before formally submitting a Dispute to arbitration, you and we may choose to informally resolve the Dispute.  If any Dispute cannot be resolved informally, you agree that any and all Disputes, including the validity of this arbitration clause and class action waiver, shall be submitted to final and binding arbitration before a single arbitrator of the American Arbitration Association (“AAA”) in a location convenient to you or telephonically. Either you or we may commence the arbitration process by submitting a written demand for arbitration with the AAA, and providing a copy to the other party.  The arbitration will be conducted in accordance with the provisions of the AAA’s Commercial Dispute Resolutions Procedures, Supplementary Procedures for Consumer-Related Disputes, in effect at the time of submission of the demand for arbitration.  Except as may be required by law as determined by the arbitrator, no party or arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. Institute of Health Sciences, L.L.C will pay all of the filing costs.  Without limiting the foregoing, YOU EXPRESSLY AGREE TO SUBMIT TO ARBITRATION ALL DISPUTES RELATING TO ANY TEXT MESSAGES OR TELEPHONE CALLS YOU RECEIVE FROM OR ON BEHALF OF US OR ANY ENTITY WITH WHOM WE MAY SHARE YOUR TELEPHONE NUMBER.  Further, we both agree that all entities with whom we share your telephone numbers shall be third party beneficiaries of this Agreement to Arbitrate Disputes, and that those entities have the same rights as Institute of Health Sciences, L.L.C to enforce this arbitration provision.

Notwithstanding the foregoing, the following shall not be subject to arbitration and may be adjudicated only in the state and federal courts of Maryland: (i) any dispute, controversy, or claim relating to or contesting the validity of our or one of our family company’s intellectual property rights and proprietary rights, including without limitation, patents, trademarks, service marks, copyrights, or trade secrets; (ii) an action by us for temporary or preliminary injunctive relief, whether prohibitive or mandatory, or other provisional relief; (iii) any legal action by us against a non-consumer; or (iv) interactions with governmental and regulatory authorities.  You expressly agree to refrain from bringing or joining any claims in any representative or class-wide capacity, including but not limited to bringing or joining any claims in any class action or any class-wide arbitration.

The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. To the fullest extent permitted by applicable law, no arbitration under this Agreement may be joined to an arbitration involving any other party subject to this Agreement, whether through a class action, private attorney general proceeding, class arbitration proceedings or otherwise.

YOU UNDERSTAND THAT YOU WOULD HAVE HAD A RIGHT TO LITIGATE IN A COURT, TO HAVE A JUDGE OR JURY DECIDE YOUR CASE AND TO BE PARTY TO A CLASS OR REPRESENTATIVE ACTION.  HOWEVER, YOU UNDERSTAND AND AGREE TO HAVE ANY CLAIMS DECIDED INDIVIDUALLY AND ONLY THROUGH ARBITRATION.  You shall have thirty (30) days from the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, to opt out of this arbitration agreement, by contacting us by email at help@hsionline.com or by mail Health Sciences Institute, PO Box 913, Frederick, MD 21705-0913. If you do not opt out by the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, then you are not eligible to opt out of this arbitration agreement.

Electronic Signatures

All information communicated on the website is considered an electronic communication.  When you communicate with us through or on the website, by text message or telephone, or via other forms of electronic media, such as e-mail, you are communicating with us electronically.  You agree that we may communicate electronically with you and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

You further acknowledge and agree that by clicking on a button labeled “ORDER NOW”, “SUBMIT”, “I ACCEPT”, “I AGREE”, “YES”, by texting a short code to us in response to a request on this website, or by clicking or similar links or buttons, you are submitting a legally binding electronic signature and are entering into a legally binding contract.  You acknowledge that your electronic submissions constitute your agreement and intent to be bound by this Agreement.  Pursuant to any applicable statutes, regulations, rules, ordinances or other laws, including without limitation the United States Electronic Signatures in Global and National Commerce Act, P.L. 106-229 (the “E-Sign Act”) or other similar statutes, YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS AND OTHER RECORDS AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED THROUGH THE WEBSITE.  Furthermore, you hereby waive any rights or requirements under any statutes, regulations, rules, ordinances or other laws in any jurisdiction which require an original signature, delivery or retention of non-electronic records, or to payments or the granting of credits by other than electronic means You may receive a physical paper copy of this contract by contacting us at help@hsionline.com.

Privacy Policy

Please read our Privacy Policy, which is incorporated herein by reference.  In the event of any conflict between these Terms and Conditions and the Privacy Policy, these Terms shall control.

Contact Us

You may contact us by telephone at 1-888-213-0764 or by email at help@hsionline.com.